# Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer

> **NCT02764268** · NA · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT02764268
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-02
- **Primary completion:** 2018-12-10
- **Final completion:** 2019-04-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02764268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02764268, "Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02764268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*